Zobrazeno 1 - 10
of 65
pro vyhledávání: '"M. Lopera Sierra"'
Autor:
E. P. Krenning, Martyn Caplin, P. Ruszniewsk, Andrew Eugene Hendifar, Beth Chasen, M. Lopera Sierra, Kjell Oberg, Edward M. Wolin, Dirk Jan Kwekkeboom, T. Hobday, J. Strosberg, Matthew H. Kulke, Erik Mittra, Richard P. Baum, David L. Bushnell
Publikováno v:
Radiotherapy and Oncology. 119:S274-S275
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c53314f9c88ba72c6bb7b196a1f5d221
https://doi.org/10.1016/s0167-8140(16)31820-5
https://doi.org/10.1016/s0167-8140(16)31820-5
Autor:
Mirco Bartolomei, Marco Chinol, Giovanni Paganelli, Stefano Papi, M. Gatti, M. Lopera Sierra, M. Fiorenza, Lisa Bodei, Chiara Maria Grana, Paola Rocca, D. Handkiewicz Junak
Publikováno v:
Biopolymers. 66:393-398
Somatostatin receptors type 2 (sst2) are expressed in high concentration on numerous neudoendocrine tumors. The successful use of radiolabeled somatostatin analogs in imaging promoted further studies in utilizing them in radiopeptide therapy. The som
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fae86c7c12f259bfbecb1fc42e8b5fb
https://doi.org/10.1002/bip.10349
https://doi.org/10.1002/bip.10349
Autor:
David L. Bushnell, Edward M. Wolin, M. Lopera Sierra, Timothy J. Hobday, Kjell Öberg, E. P. Krenning, Jonathan R. Strosberg, Richard P. Baum, Martyn Caplin, Pamela L. Kunz, P. Ruszniewski, Matthew H. Kulke, Andrew Eugene Hendifar, Beth Chasen
Publikováno v:
Annals of Oncology. 28:v146
Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE : The NETTER-1 phase III trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfcc5515ec902db94c3aab079856144a
https://doi.org/10.1093/annonc/mdx368.010
https://doi.org/10.1093/annonc/mdx368.010
Autor:
Eric P. Krenning, Paola Santoro, Dik J. Kwekkeboom, Mariani Maurizio F, Lisa Bodei, M. Lopera Sierra
Publikováno v:
Annals of Oncology. 25:iv405
Background: Currently, there is an unmet medical need for long-term effective treatment of inoperable, gastro-entero-pancreatic neuroendocrine tumours (GEPNETs). Patients having midgut neuroendocrine tumours (30-50% of all NETs) have very limited the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82ce300f855f065d25f697040e61a478
https://doi.org/10.1093/annonc/mdu345.34
https://doi.org/10.1093/annonc/mdu345.34
Autor:
Martyn Caplin, Kjell Öberg, Pamela L. Kunz, Andrew Eugene Hendifar, Matthew H. Kulke, Beth Chasen, Richard A. Baum, T. Hobday, J. Strosberg, M. Lopera Sierra, Dirk Jan Kwekkeboom, E. P. Krenning, Philippe Ruszniewski, David L. Bushnell, Edward M. Wolin
Publikováno v:
Annals of Oncology. 27:vi137
NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate : Efficacy, safety, QoL results and subgroup analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fb1d6ae38ba44937e2a5a7e2fadf8ef
https://doi.org/10.1093/annonc/mdw369.05
https://doi.org/10.1093/annonc/mdw369.05
Autor:
M. Lopera Sierra, Dirk Jan Kwekkeboom, B. Chasen, Andrew Eugene Hendifar, J. Strosberg, Edward M. Wolin, David L. Bushnell, Pamela L. Kunz, Timothy J. Hobday, P. Ruszniewski, Richard A. Baum, Matthew H. Kulke, E. P. Krenning, Kjell Öberg, M. Chaplin
Publikováno v:
Annals of Oncology. 27:ii121
4005Background: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy. The purpose of this phase III trial was to evalua...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e5fd183b98e42ee61cf1afb46a02305
https://doi.org/10.1093/annonc/mdw198.09
https://doi.org/10.1093/annonc/mdw198.09
Autor:
Erik Mittra, Kjell Öberg, Andrew Eugene Hendifar, Beth Chasen, Martyn Caplin, T. Hobday, J. Strosberg, Matthew H. Kulke, Richard P. Baum, David L. Bushnell, Edward M. Wolin, M. Lopera Sierra, Dirk Jan Kwekkeboom, Philippe Ruszniewski
Publikováno v:
European Journal of Cancer. 51:S710
177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours : Results of the phase III NETTER-1 trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3a1be498e9cbcd78ab9bf521a2e0489
https://doi.org/10.1016/s0959-8049(16)31929-3
https://doi.org/10.1016/s0959-8049(16)31929-3
Autor:
Kumar, Ujendra1 (AUTHOR) ujkumar@mail.ubc.ca
Publikováno v:
International Journal of Molecular Sciences. Jan2024, Vol. 25 Issue 1, p436. 61p.
Publikováno v:
Chemical Society Reviews; 11/7/2024, Vol. 53 Issue 21, p10409-10449, 41p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.